BioSpace News Archive

Anaeropharma Science Inc. announced on September 25 that Anaeropharma and Astellas Pharma Inc. have concluded a collaborative research agreement concerning the creation of novel anti-tumor drugs that utilizes characteristic features of Bifidobacterium longum through Anaeropharma’s proprietary platform technology, in situ Delivery and Production System (“i-DPS”).

AGC will be establishing a cGMP (*1)-compatible mammalian cell culture facility at its Chiba Plant designed to take on contracts for antibody biopharmaceutical development and production.

Applied DNA Sciences Inc. announced today that it is launching an additional system to tag the industry’s larger volume cannabis or hemp grows as part of TheraCann International’s ETCH Biotrace™ solution.

Nearly two dozen workplaces recognized for fostering employee well-being, organizational performance

Cerevance today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson’s disease.

MT.DERM GmbH, Berlin, Germany, is excited to announce its expansion into the US market of its medical microneedling device, Exceed under the brand amiea med, exclusively available to healthcare professionals.

Data in Diverse Patient Populations from Three Continents Presented at World Congress of Endourology 2018 Annual Conference

Company releases its Annual Quality Outcomes Report

Intec Pharma Ltd. today announces that three posters in support of the Company’s Phase 3 clinical development program for the Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD), will be presented at the upcoming International Congress of Parkinson’s and Movement Disorder Society (MDS 2018) being held from October 5-9, 2018 in Hong Kong.

Holmusk today announced closing of US$9.75 million in Pre-Series A financing. The financing round included funding from Heritas Venture Fund as well as participation from new and existing investors. The funds allow Holmusk to expand its footprint in USA and Europe.